BI Asset Management Fondsmaeglerselskab A S Decreases Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

BI Asset Management Fondsmaeglerselskab A S trimmed its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 42.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 37,249 shares of the company’s stock after selling 27,047 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Teva Pharmaceutical Industries were worth $1,122,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of TEVA. Harel Insurance Investments & Financial Services Ltd. raised its holdings in shares of Teva Pharmaceutical Industries by 19.2% during the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock valued at $1,402,945,000 after acquiring an additional 7,255,083 shares in the last quarter. Menora Mivtachim Holdings LTD. increased its position in Teva Pharmaceutical Industries by 1.1% during the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 38,920,294 shares of the company’s stock valued at $786,190,000 after purchasing an additional 427,000 shares during the period. Clal Insurance Enterprises Holdings Ltd raised its holdings in Teva Pharmaceutical Industries by 18.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock worth $1,171,378,000 after purchasing an additional 5,917,423 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its holdings in Teva Pharmaceutical Industries by 14.8% in the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 37,402,212 shares of the company’s stock worth $1,167,323,000 after purchasing an additional 4,820,000 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter valued at about $1,098,060,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Truist Financial boosted their price target on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Monday, April 20th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. Bank of America upped their price target on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 9th. Finally, JPMorgan Chase & Co. raised their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.78.

Teva Pharmaceutical Industries Trading Up 3.0%

NYSE:TEVA opened at $34.20 on Thursday. The stock has a market cap of $39.33 billion, a price-to-earnings ratio of 25.72, a PEG ratio of 3.74 and a beta of 0.84. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70. The company’s 50 day moving average price is $33.66 and its 200-day moving average price is $32.35. Teva Pharmaceutical Industries Ltd. has a 52 week low of $14.99 and a 52 week high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The business had revenue of $3.98 billion for the quarter. On average, equities research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.14 earnings per share for the current fiscal year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, insider Mark Sabag sold 144,180 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $34.99, for a total value of $5,044,858.20. Following the completion of the sale, the insider directly owned 80,760 shares in the company, valued at $2,825,792.40. The trade was a 64.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Christine Fox sold 21,258 shares of the business’s stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $35.31, for a total transaction of $750,619.98. Following the sale, the executive vice president owned 63,647 shares of the company’s stock, valued at approximately $2,247,375.57. This represents a 25.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 465,931 shares of company stock worth $16,332,989. 0.54% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.